journal article·2023-02-26

Acidity‐Triggered Transformable Polypeptide Self‐Assembly to Initiate Tumor‐Specific Biomineralization

Yang Liu, Zhongyu Jiang, Shizheng Tong, Yifu Sun, Yu Zhang, Jiayuan Zhang, Duoyi Zhao, Yuanzhen Su, Jianxun Ding, Xuesi Chen

Publisher page

Abstract

Biomineralization is a normal physiological process that includes nucleation, crystal growth, phase transformation, and orientation evolution. Notably, artificially induced biomineralization in the tumor tissue has emerged as an unconventional yet promising modality for malignancy therapy. However, the modest ion-chelating capabilities of carboxyl-containing biomineralization initiators lead to a deficient blockade, thus compromising antitumor efficacy. Herein, a biomineralization-inducing nanoparticle (BINP) is developed for blockade therapy of osteosarcoma. BINP is composed of dodecylamine-poly((γ-dodecyl-l-glutamate)-co-(l-histidine))-block-poly(l-glutamate-graft-alendronate) and combines a cytomembrane-insertion moiety, a tumor-microenvironment (TME)-responsive component, and an ion-chelating motif. After intravenous injection into osteosarcoma-bearing mice, BINP responds to the acidic TME to expose the dodecyl group on the surface of the expanded nanoparticles, facilitating their cytomembrane insertion. Subsequently, the protruding bisphosphonic acid group triggers continuous ion deposition to construct a mineralized barrier around the tumor, which blocks substance exchange between the tumor and surrounding normal tissues. The BINP-mediated blockade therapy displays tumor inhibition rates of 59.3% and 52.1% for subcutaneous and orthotopic osteosarcomas, respectively, compared with the Control group. In addition, the suppression of osteoclasts by the alendronate moiety alleviates bone dissolution and further inhibits pulmonary metastases. Hence, the BINP-initiated selective biomineralization provides a promising alternative for clinical osteosarcoma therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Polymer Ecomaterials Changchun Institute of Applied Chemistry Chinese Academy of Sciences 5625 Renmin Street Changchun 130022 P. R. China

School of Applied Chemistry and Engineering University of Science and Technology of China 96 Jinzhai Road Hefei 230026 P. R. China

Department of Orthopedics The Fourth Affiliated Hospital of China Medical University 4 Chongshan East Road Shenyang 110032 P. R. China

Department of Orthopedics The Second Hospital of Jilin University 218 Ziqiang Street Changchun 130041 P. R. China

School of Life Sciences Jilin University 2699 Qianjin Street Changchun 130022 P. R. China

Jilin Biomedical Polymers Engineering Laboratory Changchun Institute of Applied Chemistry Chinese Academy of Sciences 5625 Renmin Street Changchun 130022 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (62)

Show source-provided references
1. Arnold A. · Nat. Rev. Endocrinol. · 2021 · 17 · 26110.1038/s41574-021-00477-2 ↗
2. Omelon S. J. · Chem. Rev. · 2008 · 108 · 469410.1021/cr0782527 ↗
3. Yao S. · Adv. Mater. · 2017 · 29 · 160590310.1002/adma.201605903 ↗
4. DeRocher K. A. · Nature · 2020 · 583 · 6610.1038/s41586-020-2433-3 ↗
5. Reznikov N. · Nat. Rev. Mater. · 2016 · 1 · 1604110.1038/natrevmats.2016.41 ↗
6. Rogers M. A. · Nat. Rev. Cardiol. · 2019 · 16 · 26110.1038/s41569-018-0123-8 ↗
7. Howles S. A. · Nat. Rev. Urol. · 2020 · 17 · 40710.1038/s41585-020-0332-x ↗
8. Vidavsky N. · Adv. Healthcare Mater. · 2021 · 10 · 200127110.1002/adhm.202001271 ↗
9. Wu J. · Adv. Funct. Mater. · 2021 · 31 · 210128410.1002/adfm.202101284 ↗
10. Zhou Y. · Anti‐Cancer Drugs · 2019 · 30 · 19510.1097/CAD.0000000000000726 ↗
11. Zhao R. · Angew. Chem. Int. Ed. · 2016 · 55 · 522510.1002/anie.201601364 ↗
12. Tang N. · Angew. Chem., Int. Ed. · 2021 · 60 · 650910.1002/anie.202016122 ↗
13. Kahil K. · J. Am. Chem. Soc. · 2021 · 143 · 2110010.1021/jacs.1c09174 ↗
14. Kim Y.‐Y. · Nat. Commun. · 2019 · 10 · 568210.1038/s41467-019-13422-9 ↗
15. Tang S. · Int. J. Oral. Sci. · 2021 · 13 · 4210.1038/s41368-021-00147-z ↗
16. Chow L. C. · Dent. Mater. J. · 2009 · 28 · 110.4012/dmj.28.1 ↗
17. Li Z. · Ind. Eng. Chem. Res. · 2006 · 45 · 451710.1021/ie0600339 ↗
18. Brečević L. · J. Cryst. Growth · 1989 · 98 · 50410.1016/0022-0248(89)90168-1 ↗
19. Bullard J. W. · J. Am. Ceram. Soc. · 2010 · 93 · 189410.1111/j.1551-2916.2010.03656.x ↗
20. Jiang Z. · Adv. Mater. · 2022 · 34 · 211009410.1002/adma.202110094 ↗
21. Kumazaki K. · Nature · 2014 · 509 · 51610.1038/nature13167 ↗
22. Uvyn A. · Angew. Chem., Int. Ed. · 2019 · 58 · 1298810.1002/anie.201905093 ↗
23. Zhang Z. · Nat. Commun. · 2018 · 9 · 137710.1038/s41467-018-03779-8 ↗
24. Wu H. · Biomaterials · 2013 · 34 · 121310.1016/j.biomaterials.2012.08.072 ↗
25. Mihailescu M. · J. Am. Chem. Soc. · 2019 · 141 · 983710.1021/jacs.9b00440 ↗
26. Mideros‐Mora C. · Nat. Commun. · 2020 · 11 · 76910.1038/s41467-020-14540-5 ↗
27. Yang Z. · Chem. Commun. · 2006 · 7 · 73810.1039/b516133a ↗
28. Kim Y.‐H. · Nat. Commun. · 2020 · 11 · 136510.1038/s41467-020-15152-9 ↗
29. Cole L. E. · Adv. Drug Delivery Rev. · 2016 · 99 · 1210.1016/j.addr.2015.10.005 ↗
30. D'Oronzo S. · Bone · 2021 · 147 · 11590710.1016/j.bone.2021.115907 ↗
31. Gao X. · Biomaterials · 2021 · 265 · 12040410.1016/j.biomaterials.2020.120404 ↗
32. Vitte C. · Endocrinology · 1996 · 137 · 232410.1210/endo.137.6.8641182 ↗
33. Takagi Y. · Microscopy · 2021 · 70 · 30210.1093/jmicro/dfaa073 ↗
34. Jobke B. · Bone · 2014 · 59 · 3710.1016/j.bone.2013.10.024 ↗
35. Qiu J. · Biomaterials · 2022 · 285 · 12154110.1016/j.biomaterials.2022.121541 ↗
36. Guo S. · Nano Today · 2022 · 43 · 10139610.1016/j.nantod.2022.101396 ↗
37. Wang L. · Chem. Rev. · 2008 · 108 · 462810.1021/cr0782574 ↗
38. Kim D. · Nat. Commun. · 2018 · 9 · 96210.1038/s41467-018-03041-1 ↗
39. Zhao W. · Cancer Res. · 2016 · 76 · 203710.1158/0008-5472.CAN-15-1970 ↗
40. Kopecka J. · Drug Resist. Updat. · 2020 · 49 · 10067010.1016/j.drup.2019.100670 ↗
41. Zalba S. · Cancer Treat. Rev. · 2017 · 52 · 4810.1016/j.ctrv.2016.10.008 ↗
42. Misaghi A. · SICOT J. · 2018 · 4 · 1210.1051/sicotj/2017028 ↗
43. Gill J. · Nat. Rev. Clin. Oncol. · 2021 · 18 · 60910.1038/s41571-021-00519-8 ↗
44. Harrison D. J. · Expert Rev. Anticancer Ther. · 2018 · 18 · 3910.1080/14737140.2018.1413939 ↗
45. Meltzer P. S. · N. Engl. J. Med. · 2021 · 385 · 206610.1056/NEJMra2103423 ↗
46. Li Y. · Cell. Physiol. Biochem. · 2015 · 37 · 237510.1159/000438591 ↗
47. Ho P. W. M. · Oncogene · 2015 · 34 · 292210.1038/onc.2014.217 ↗
48. Al‐Khan A. A. · Front. Vet. Sci. · 2021 · 8 · 63761410.3389/fvets.2021.637614 ↗
49. Cairns R. A. · Nat. Rev. Cancer · 2011 · 11 · 8510.1038/nrc2981 ↗
50. Avnet S. · Int. J. Oncol. · 2008 · 33 · 1231
51. He C. · Nano Today · 2021 · 41 · 10129710.1016/j.nantod.2021.101297 ↗
52. Kim S. H. · Cancer Med. · 2017 · 6 · 131110.1002/cam4.1022 ↗
53. Arthur‐Baidoo E. · Angew. Chem., Int. Ed. · 2020 · 59 · 1717710.1002/anie.202006675 ↗
54. Junnotula V. · J. Am. Chem. Soc. · 2009 · 131 · 101510.1021/ja8049645 ↗
55. Yang S. · Adv. Mater. · 2019 · 31 · 180595510.1002/adma.201805955 ↗
56. Brown J. M. · Nat. Rev. Cancer · 2004 · 4 · 43710.1038/nrc1367 ↗
57. Anderson R. F. · J. Am. Chem. Soc. · 2006 · 128 · 24510.1021/ja0559101 ↗
58. Norregaard K. S. · Int. J. Mol. Sci. · 2021 · 22 · 686510.3390/ijms22136865 ↗
59. Navet B. · Cancers · 2018 · 10 · 39810.3390/cancers10110398 ↗
60. Ory B. · Cancer · 2005 · 104 · 252210.1002/cncr.21530 ↗
61. Akiyama T. · Mol. Cancer Ther. · 2008 · 7 · 346110.1158/1535-7163.MCT-08-0530 ↗
62. Fisher J. E. · Proc. Natl. Acad. Sci. USA · 1999 · 96 · 13310.1073/pnas.96.1.133 ↗